Abstracts Archive - Page 919 of 2425 - ACR Meeting Abstracts

Abstract Number: 2410 • 2019 ACR/ARP Annual Meeting
Using External Data to Estimate Omitted Variables in Observational Data: A Plasmode Simulation Study Investigating the Relationship Between Osteoarthritis and Cardiovascular Diseases to Compare Alternative Approaches in Imputing the Body Mass Index Variable
Mohammad Atiquzzaman¹, Mohammad Karim ², Jacek Kopec ³, Hubert Wong ⁴, Mary De Vera ⁵ and Aslam Anis ², ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Surrey, BC, Canada, ²School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: BMI is a well-known confounding factor in the association between osteoarthritis (OA) and cardiovascular diseases (CVD). However, BMI is not usually recorded in administrative…
Abstract Number: 2411 • 2019 ACR/ARP Annual Meeting
Casting a Wide Net: Comparing Strategies for Recruiting 18-35-year-olds with Rheumatic Disease as Study Participants
Arif Jetha¹, Lori Tucker ², Julie Bowring ³, Catherine L. Backman ⁴, Laurie Proulx ⁵, Vicki Kristman ⁶ and Monique A.M. Gignac ³, ¹Institute for Work & Health, Toronto, ON, Canada, ²British Columbia Children’s Hospital, Vancouver, Canada, ³Institute for Work & Health, Toronto, Canada, ⁴University of British Columbia, Vancouver, Canada, ⁵Canadian Arthritis Patient Alliance, Ottawa, Canada, ⁶Lakehead University, Thunder Bay, Canada
Background/Purpose: Young adulthood is a unique life phase that spans 18-35 years, and is characterized by healthcare, educational, vocational and social transitions. Experiences in young…
Abstract Number: 2412 • 2019 ACR/ARP Annual Meeting
Use of Minimal Important Difference (MID) in Randomized Clinical Trials of Pain in Osteoarthritis
Lavalley Michael¹, Matthew Parkes ², Daniel White ³, Stephan Reichebach ⁴, Timothy McAlindon ⁵ and David Felson ⁶, ¹Boston University, Boston, ²University of Manchester, Manchester, England, United Kingdom, ³University of Delaware, Newark, DE, ⁴University of Bern, Bern, Switzerland, ⁵Tufts Medical Center, Boston, MA, ⁶Boston University School of Medicine, Department of Rheumatology, Boston
Background/Purpose: Minimal important differences (MID), based on within-subject evaluation of attaining an improvement in a continuous outcome such as a pain scale, are important for…
Abstract Number: 2413 • 2019 ACR/ARP Annual Meeting
LOU064: A Highly Selective and Potent Covalent Oral BTK Inhibitor with Promising Pharmacodynamic Efficacy on B Cells for Sjoegren’s Syndrome
Bruno Cenni¹, Peter End ¹, Maciej Cabanski ¹, Annamaria Jakab ¹, Enrico Funhoff ¹, Magdalena Kistowska ¹, Arvind Kinhikar ², Alessio Maiolica ¹, Masaru Hirano ³, Barbara Nuesslein-Hildesheim ¹, Amanda Littlewood-Evans ¹, Daniela Angst ¹, Robert Pulz ⁴ and Martin Kaul ¹, ¹Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Novartis Institutes for BioMedical Research, Cambridge, MA, ³Novartis Institutes for BioMedical Research, Tokyo, Japan, ⁴Novartis Institues for BioMedical Research, Basel, Switzerland
Background/Purpose: Bruton’s Tyrosine Kinase (BTK) is a cytoplasmic tyrosine kinase selectively expressed in B cells, macrophages, mast cells and basophils. The essential role of BTK…
Abstract Number: 2414 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial
Jolien van Nimwegen¹, Esther Mossel ¹, Robin Wijnsma ¹, Greetje van Zuiden ¹, Konstantina Delli ¹, Alja Stel ¹, Bert van der vegt ¹, Erlin Haacke ¹, Lisette Olie ¹, Leonie Los ¹, Gwenny Verstappen ¹, Sarah Pringle ¹, Fred Spijkervet ¹, Frans Kroese ¹, Arjan Vissink ¹, Suzanne Arends ² and Hendrika Bootsma ³, ¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, ³University of Groningen, Groningen, Netherlands
Background/Purpose: Abatacept (CTLA-4-Ig) targets the CD80/CD86:CD28 co-stimulatory pathway required for full T-cell activation and T-cell dependent activation of B-cells. The Abatacept Sjögren Active Patients phase…
Abstract Number: 2415 • 2019 ACR/ARP Annual Meeting
Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren ’s Syndrome (pSS) and RA Patients
Yash Gandhi¹, Mehmooda Shaikh ², Blisse Vakkalagadda ¹, Grigor Abelian ¹, Neelanjana Ray ¹, Robert Wong ¹ and Bindu Murthy ¹, ¹Bristol-Myers Squibb, Princeton, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Abatacept (ABA) has proven efficacy in autoimmune diseases and is being evaluated in pSS. The purpose of this investigation was to evaluate the pharmacokinetics…
Abstract Number: 2416 • 2019 ACR/ARP Annual Meeting
ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome
Stacey Dillon¹, Lawrence Evans ¹, Katherine Lewis ¹, Susan Bort ¹, Erika Rickel ¹, Jing Yang ¹, Martin Wolfson ¹, Kayla Susmilch ¹, Sherri Mudri ¹, Steven Levin ¹, Janhavi Bhandari ¹, Fariha Ahmed-Qadri ¹, Mark Rixon ¹, Jan Hillson ², Stanford Peng ¹ and Kristine Swiderek ¹, ¹Alpine Immune Sciences, Seattle, WA, ²Alpine Immune Sciences, Seattle, WI
Background/Purpose: ALPN-101 is an Fc fusion protein of a human inducible T cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgDTM) designed to inhibit simultaneously the…
Abstract Number: 2417 • 2019 ACR/ARP Annual Meeting
A Phase 2a Study of MEDI5872 (AMG557), a Fully Human Anti-ICOS Ligand Monoclonal Antibody in Patients with Primary Sjögren’s Syndrome
Xavier Mariette¹, Michele Bombardieri ², Ilias Alevizos ³, Rachel Moate ⁴, Barbara Sullivan ⁵, Ghaith Noaiseh ⁶, Marika Kvarnström ⁷, William Rees ³, Liangwei Wang ³ and Gabor Illei ³, ¹Université Paris-Sud, Paris, France, Paris, Centre, France, ²Queen Mary University of London, London, UK, London, United Kingdom, ³Viela Bio, Gaithersburg, MD, USA, Gaithersburg, MD, ⁴AstraZeneca, Cambridge, UK, Cambridge, United Kingdom, ⁵Amgen Inc., South San Francisco, CA, USA, South San Francisco, CA, ⁶University of Pittsburgh, PA, USA, Pittsburgh, PA, ⁷Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: The interaction of inducible T cell costimulatory ligand (ICOSL) and the ICOS receptor is key in the pathogenesis of primary Sjögren’s syndrome (pSS). MEDI5872…
Abstract Number: 2418 • 2019 ACR/ARP Annual Meeting
Tofacitinib Inhibits Increased Inflammatory Marker Expression in a Human Salivary Cell Line Deficient in Autophagy: A Model of Sjögren’s Syndrome
María José Barrera ¹, Sergio Aguilera², Patricia Carvajal ³, Isabel Castro ⁴, Sergio González ⁵, Claudio Molina ¹, Soledad Matus ⁶, Daniela Jara ³ and María Julieta González ³, ¹Facultad de Odontología, Universidad San Sebastián, Santiago, Chile, ²Clínica INDISA, Santiago, Chile, ³ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Chile, ⁴Departamento Tecnología Médica, Universidad de Chile, Santiago, Chile, ⁵Escuela de Odontología, Universidad Mayor, Santiago, Chile, ⁶Fundación Ciencia & Vida, Santiago, Chile, Santiago, Chile
Background/Purpose: Sjögren’s syndrome (SS) is an immune-mediated exocrinopathy, where defects in autophagy could contribute to the pathogenesis. Minor labial salivary glands (MLSG) of primary SS…
Abstract Number: 2419 • 2019 ACR/ARP Annual Meeting
An ex-vivo Assay to Evaluate the Efficacy of Different Treatments for Inhibiting B Lymphocytes Activation by Salivary Gland Epithelial Cells in Sjögren’s Syndrome
Elodie Rivière¹, Juliette Pascaud ², Audrey Paoletti ³, Bineta Ly ³, Gaetane Nocturne ⁴ and Xavier Mariette ⁵, ¹IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre ; Arthritis R&D, France, Paris, France, ²IMVA - IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre, Paris, France, ³IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre, Le Kremlin Bicetre, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France., Paris, France, ⁵Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: Primary Sjögren's syndrome (pSS) is an auto-immune disorder characterized by a chronic hyperactivation of B lymphocytes. We previously showed that salivary gland epithelial cells…
Abstract Number: 2420 • 2019 ACR/ARP Annual Meeting
Role of T Follicular Helper Cells and T Peripheral Helper Cells in the Activation of B Cells in Sjögren Syndrome
Anastasia Dupré¹, Juliette Pascaud ¹, Elodie Rivière ², Michael Mingueneau ³, Gaetane Nocturne ⁴ and Xavier Mariette ⁵, ¹IMVA - IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre, Paris, France, ²IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre ; Arthritis R&D, France, Paris, France, ³Biomarker Discovery Platform UTechS CB, Hub de Bioinformatique et biostatistique, C3IB, Institut Pasteur, Paris, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France., Paris, France, ⁵Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: Primary Sjögren's Syndrome (pSS) is a rare systemic autoimmune disease characterized by a dysregulation of cellular and humoral immunity, leading to a hyper-activation of…
Abstract Number: 2421 • 2019 ACR/ARP Annual Meeting
Circulating CCR7loPD-1hi Follicular Helper T Cells Indicate Disease Activity and Glandular Inflammation in Patients with Primary Sjögren’s Syndrome
Ji-Won Kim¹, Jaeseon Lee ², Ui Hong Jung ¹, Sung-Hoon Park ¹, Jennifer Lee ³, Seung-Ki Kwok ³ and Sung-Hwan Park ³, ¹Catholic University of Daegu School of Medicine, Daegu, Republic of Korea, ²Catholic University of Korea, College of Medicine, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Background/Purpose: Since primary Sjögren’s syndrome (pSS) is an autoummune disease of B cell hyperactivity and pathologic autoantibody response, follicular helper T (Tfh) cells and follicular…
Abstract Number: 2422 • 2019 ACR/ARP Annual Meeting
Increased Apoptosis and Compromised Suppressive Capacity of Regulatory T Cells in Primary Sjögren’s Syndrome
Min Feng¹, Xiangcong Zhao ¹ and Jing Luo ¹, ¹the second hospital of shanxi medical university, Taiyuan, China (People's Republic)
Background/Purpose: To investigate the apoptosis and suppressive function of regulatory T cells (Tregs) in primary Sjögren’s syndrome (pSS), and the effect of low-dose IL-2 on apoptosis of Tregs.Methods:…
Abstract Number: 2423 • 2019 ACR/ARP Annual Meeting
In Primary Sjogren’s Syndrome (pSS) IL7 Promotes the Crosstalk Between T Lymphocytes and Salivary Gland Epithelial Cells and Participates to IFN Signature
Gaetane Nocturne¹, Juliette Pascaud ², Elodie Rivière ³, Alexandre Virone ⁴, Anastasia Dupré ², Vanessa Gauttier ⁵, Nicolas Poirier ⁵ and Xavier Mariette ⁶, ¹Université Paris Sud, Le Kremlin Bicetre, France, ²IMVA - IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre, Paris, France, ³IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre ; Arthritis R&D, France, Paris, France, ⁴Université Paris Sud, Le Kremlin Bicetre, ⁵OSE Immunotherapeutics, Nantes, France, ⁶Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: pSS is characterized by lymphocytic infiltration of salivary gland epithelial cells (SGEC). This infiltrate is made of T (TL) and B (BL) lymphocytes. SGEC…
Abstract Number: 2424 • 2019 ACR/ARP Annual Meeting
RORγt Antagonist Attenuates Experimental Sialadenitis Like Sjögren’s Syndrome via Inhibition of CD25 Expression on CD4+ T Cells
Yuko Ono¹, Hiroto Tsuboi ², Masafumi Moriyama ³, Hiroyuki Takahashi ², Fumika Honda ², Saori Abe ², Yuya Kondo ², Isao Matsumoto ², Seiji Nakamura ⁴ and Takayuki Sumida ², ¹Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Science, Faculty of Dental Science, Kyushu University, Tsukuba, Japan, ²Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ³Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Science, Faculty of Dental Science, Kyusyu University, Fukuoka, Japan, ⁴Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Science, Faculty of Dental Science, Kyusyu University, Fukuoka
Background/Purpose: Our previous study demonstrated that T cells specific RORγt transgenic-mice under human CD2 promoter (RORγt-Tg mice) developed severe spontaneous sialadenitis like Sjögren’s syndrome (SS)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].